Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Dysport (abobotulinumtoxinA) for the Treatment of Lower Limb Spasticity in Paediatric Patients

Drug (Brand / Generic)

Dysport (abobotulinumtoxinA)

Therapy Class

Acetylcholine release inhibitor and neuromuscular blocking agent

Current Indication

Lower limb spasticity

Developer

Ipsen Biopharmaceuticals

Market Sector

Musculoskeletal

Development Status

Approved in the US
Expand

Go Top